Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- Trading 59% below Graham Number ($19.90) — significant margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 17.3% — good return on equity
- Revenue declining 23% annually
CryoPort, Inc. - Common Stock (CYRX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $409 million . Key value metrics: P/E ratio 4.7, P/B ratio 0.81, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CryoPort, Inc. - Common Stock — Fundamental Analysis Summary
CryoPort, Inc. - Common Stock (CYRX) is trading 59% below its Graham Number of $19.90 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 4.7x.
On financial health, CYRX shows a moderate Piotroski F-Score of 4/9, and solid return on equity of 17.3% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.52.
StockPik's composite Value Score for CYRX is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CYRX reports a solid gross margin of 46.3% (sector average: 33.5%) and a negative operating margin of -24.3%.
CYRX shows revenue declining at 23% year-over-year, with earnings growing at 168%.